# EverFlex Post Approval Study

Study · id `cardio:ct-nct01680835` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01680835](<https://clinicaltrials.gov/study/NCT01680835>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01680835

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 108 participants.

## Technical summary

Registry record NCT01680835. Allocation not applicable; no masking; primary purpose treatment. Start 2013-01-14 (actual); primary completion 2018-10-23 (actual). Results posted on 2019-12-26.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 108 participants (enrolled count; ClinicalTrials.gov record NCT01680835, source copy `cardio:ctgov-nct01680835-2019-12-26`, retrieved 2026-10-31)
- Started: 2013-01-14 (actual) (ClinicalTrials.gov record NCT01680835, source copy `cardio:ctgov-nct01680835-2019-12-26`, retrieved 2026-10-31)
- Primary completion: 2018-10-23 (actual) (ClinicalTrials.gov record NCT01680835, source copy `cardio:ctgov-nct01680835-2019-12-26`, retrieved 2026-10-31)
- Completion: 2019-02-04 (actual) (ClinicalTrials.gov record NCT01680835, source copy `cardio:ctgov-nct01680835-2019-12-26`, retrieved 2026-10-31)
- Results first posted: 2019-12-26 (ClinicalTrials.gov record NCT01680835, source copy `cardio:ctgov-nct01680835-2019-12-26`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT01680835, source copy `cardio:ctgov-nct01680835-2019-12-26`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01680835-2019-12-26`, retrieved 2026-10-31)

## The registry's words

- Brief title: EverFlex Post Approval Study
- Acronym: DURABILITY PAS
- Condition: Peripheral Arterial Disease
- Condition: Lower Extremity Arterial Disease
- Intervention (Device): EverFlex™ Self-Expanding Peripheral Stent System
- Lead sponsor: Medtronic Endovascular
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Peripheral artery disease (`cardio:peripheral-artery-disease`)
- Registry lists this organization as the lead sponsor: Medtronic Endovascular (`cardio:org-medtronic-endovascular`)

## Provenance

Content hash: 83e0d9e81d62592713ed200a685d47af6e650d63c40893eeecbf1bded1af0099
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
